Stephen C. Blacklow

Stephen C. Blacklow

Auto-generated profile, based on publicly available information

Stephen C. Blacklow

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Developmental Cell
Verified
Journal Article
Closed access
WGWendy R. Gordon
Wendy R. Gordon
BZBrandon Zimmerman
Brandon Zimmerman
LHLi He
Li He
LMLaura J. Miles
Laura J. Miles
JHJiuhong Huang
Jiuhong Huang
SBStephen C. Blacklow
Stephen C. Blacklow

1 November 2016 in Cell
Verified
Journal Article
Closed access
BZBrandon Zimmerman
Brandon Zimmerman
BKBrendan Kelly
Brendan Kelly
BMBrian J. McMillan
Brian J. McMillan
TSTom C.M. Seegar
Tom C.M. Seegar
RDRon O. Dror
Ron O. Dror
SBStephen C. Blacklow
Stephen C. Blacklow

3 February 2021 in Annual Review of Biophysics
Verified
Journal Article
Closed access
DSDavid Sprinzak
David Sprinzak
SBStephen C. Blacklow
Stephen C. Blacklow
Notch signaling is a conserved system of communication between adjacent cells, influencing numerous cell fate decisions in the development of multicellular organisms. Aberrant signaling is also implicated in many human pathologies. At its core, Notch has a mechanotransduction module that decodes receptor–ligand engagement at the cell surface under force to permit proteolytic cleavage of the receptor, leading to the release of the Notch intracellular domain (NICD). NICD enters the nucleus and acts as a transcriptional effector to regulate expression of Notch-responsive genes. In this article, we review and integrate current understanding of the detailed molecular basis for Notch signal transduction, highlighting quantitative, structural, and dynamic features of this developmentally central signaling mechanism. We discuss the implications of this mechanistic understanding for the functionality of the signaling pathway in different molecular and cellular contexts.

30 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJonathan R. LaRochelle
Jonathan R. LaRochelle
MFMichelle Fodor
Michelle Fodor
VVVidyasiri Vemulapalli
Vidyasiri Vemulapalli
MMMorvarid Mohseni
Morvarid Mohseni
PWPing Wang
Ping Wang
SBStephen C. Blacklow
Stephen C. Blacklow
Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers. The allosteric inhibitor SHP099 stabilizes the wild-type SHP2 enzyme in an autoinhibited conformation that is itself destabilized by oncogenic mutations. Here, we report the impact of the highly activated and most frequently observed mutation, E76K, on the structure of SHP2, and investigate the effect of E76K and other oncogenic mutations on allosteric inhibition by SHP099. SHP2E76K adopts an open conformation but can be restored to the closed, autoinhibited conformation, near-identical to the unoccupied wild-type enzyme, when complexed with SHP099. SHP099 inhibitory activity against oncogenic SHP2 variants in vitro and in cells scales inversely with the activating strength of the mutation, indicating that either oncoselective or vastly more potent inhibitors will be necessary to suppress oncogenic signaling by the most strongly activating SHP2 mutations in cancer.

1 December 2017 in Cell
Verified
Journal Article
Closed access
TSTom C.M. Seegar
Tom C.M. Seegar
LKLauren B. Killingsworth
Lauren B. Killingsworth
NSNayanendu Saha
Nayanendu Saha
PMPeter A. Meyer
Peter A. Meyer
DPDhabaleswar Patra
Dhabaleswar Patra
SBStephen C. Blacklow
Stephen C. Blacklow

1 August 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MAMarie Blanke Andrawes
Marie Blanke Andrawes
XXXiang Xu
Xiang Xu
HLHong Liu
Hong Liu
SFScott B. Ficarro
Scott B. Ficarro
JMJarrod A. Marto
Jarrod A. Marto
SBStephen C. Blacklow
Stephen C. Blacklow
Notch signaling makes critical contributions to cell fate determination in all metazoan organisms, yet remarkably little is known about the binding affinity of the four mammalian Notch receptors for their three Delta-like and two Jagged family ligands. Here, we utilized signaling assays and biochemical studies of purified recombinant ligand and receptor molecules to investigate the differences in signaling behavior and intrinsic affinity between Notch1-Dll1 and Notch1-Dll4 complexes. Systematic deletion mutagenesis of the human Notch1 ectodomain revealed that epidermal growth factor (EGF) repeats 6–15 are sufficient to maintain signaling in a reporter assay at levels comparable with the full-length receptor, and identified important contributions from EGF repeats 8–10 in conveying an activating signal in response to either Dll1 or Dll4. Truncation studies of the Dll1 and Dll4 ectodomains showed that the MNNL-EGF3 region was both necessary and sufficient for full activation. Plate-based and cell binding assays revealed a specific, calcium-dependent interaction between cell-surface and recombinant Notch receptors and ligand molecules. Finally, direct measurement of the binding affinity of Notch1 EGF repeats 6–15 for Dll1 and Dll4 revealed that Dll4 binds with at least an order of magnitude higher affinity than Dll1. Together, these studies give new insights into the features of ligand recognition by Notch1, and highlight how intrinsic differences in the biochemical behavior of receptor-ligand complexes can influence receptor-mediated responses of developmental signaling pathways.